Assembly Biosciences Announces September Conference Participation

INDIANAPOLIS, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome, today announced participation at various upcoming conferences:

• International HBV Meeting - Washington, DC
  Date: September 5, 2017 
  Poster Presentation: "Using a Toolbox of New and Established Mechanistic Assays to Determine How Core Protein Allosteric Modifiers (CpAMs) Inhibit HBV cccDNA Production" 
  Presenter: Dawai Cai, PhD., Principal Scientist II, Assembly Biosciences 
  
  
• Citi's 12^th Annual Biotech Conference - Boston 
  Date: September 6-7, 2017
  
  
• Bugs, Drugs and Beyond: Translational Approaches to the Microbiome - Menlo Park 
  Date: September 12, 2017 
  Panel: From Validation to Regulation: Breaking Down Barriers to Microbiome Progress 
  Presenter: Miguel Barbosa, PhD., Chief Scientific Officer, Microbiome Program, Assembly Biosciences
  
  
• Discovery on Target: Targeting HBV - Boston 
  Date: September 25, 2017  
  Panel: Targeting HBV Core Protein to Achieve Higher Cure Rates 
  Presenter: Richard Colonno, PhD., Chief Scientific Officer, HBV Program, Assembly Biosciences
  
  
• Cantor Fitzgerald Annual Healthcare Conference - New York
  Date: September 25-27, 2017
  
  
• Chicago Microbiome - University of Chicago, Chicago 
  Date: September 26-27, 2017 
  Presentation: Realizing the Promise of the Microbiome: Using Rigourous Pharmaceutical Principles of Drug Development 
  Presenter: Chris Howerton, PhD., Head of Microbiome Discovery Platform, Assembly Biosciences

Copies of the poster and presentations will be available in the Events and Presentations section of the Company's website at www.assemblybio.com.

About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. Assembly's HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL^®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Assembly is developing a robust pipeline of product candidates in multiple disease indications. For more information, visit www.assemblybio.com.

Forward-Looking Statement
The information in this press release contains forward-looking statements regarding future events, including statements about the clinical and therapeutic potential of Assembly's development programs. Certain forward-looking statements may be identified by reference to a future period or periods or by use of forward-looking terminology such as "designed" or "developing."  Assembly intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Assembly are more fully detailed under the heading "Risk Factors" in Assembly's Annual Report on Form 10-K for the year ended December 31, 2016, and Quarterly Report on Form 10-Q for the quarter ending June 30, 2017 filed with the Securities and Exchange Commission. Except as required by law, Assembly assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. 

Contacts 

Assembly Biosciences, Inc.



Investors: 

Lauren Glaser

(415) 521-3828

lglaser@assemblybio.com



Media:

Barbara Lindheim

(212) 584-2276

barbara@assemblybio.com

News Provided by Acquire Media